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Introduction 
This is the report of the Joint Committee on Health’s detailed scrutiny of the 
Cannabis for Medicinal Use Regulation Bill 2016, which aims to make cannabis 
available for medicinal use through licenced pharmacies. 
The Bill was referred to the Select Committee on Health by order of the Dáil of 1 
December 2016. The Joint Committee on Health decided to conduct Detailed 
Scrutiny of the Bill before it proceeded to Committee Stage. 
 
Purpose of the Bill 
The purpose of the Bill is to make cannabis available as a medicinal product for 
individuals who receive certification from a registered doctor. To that end, it 
proposes the foundation of a Cannabis Regulatory Authority which would 
regulate the sale of medicinal cannabis and oversee a system allowing 
pharmacies to receive licences to sell medicinal cannabis.  
 
Procedural basis for Scrutiny 
Private Members Bills referred to Select Committee are subject to the provisions 
of Standing Order 141(2) [Dáil] which provides that a Select Committee “shall 
undertake detailed scrutiny of the provisions of such Bills….and shall report 
thereon to the Dáil prior to Committee stage consideration….” unless the 
Committee decides in relation to a particular Bill that detailed scrutiny is not 
necessary. 
Paragraph (3) of Standing Order 141 permits scrutiny of the Bill in Joint 
Committee, viz. “Nothing in this Standing Order shall preclude a Joint Committee 
from undertaking detailed scrutiny as set out in paragraph (2) and reporting 
thereon to both Houses prior to Committee Stage consideration of the Bill by the 
Select Committee.” 
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Detailed Scrutiny 
The Committee met on 5 April 2017 when it heard evidence from the Bill’s 
sponsor, Deputy Gino Kenny, and on 13 April 2017 when it heard evidence from 
officials from the Department of Health, on their respective views on the content 
of the Bill. 
The Committee’s views on the subject of medicinal cannabis are also informed 
by the report it agreed on 19 January 20171. In that report, the Committee 
noted that, despite encouraging medicinal possibilities offered by cannabis and 
cannabinoids, there is still a shortage of peer-reviewed evidence for the efficacy 
and safety of cannabinoid treatment for many conditions, and that potential 
benefits had to be balanced against risks. 
While the Committee appreciates Deputy Kenny’s statement that his aim in 
sponsoring the Bill is to alleviate unnecessary suffering, aspects of the Bill cause 
the Committee to be concerned that it may not be possible to reconcile it with 
the Committee’s above-mentioned careful approach to medicinal cannabis. 
Cannabis Regulatory Authority  
Firstly, the Committee is concerned that the Bill’s proposed establishment of a 
Cannabis Regulatory Authority to regulate cannabis, which would be deemed a 
medicinal product, would undermine the current regulatory framework for 
medicine in the State, which involves the Health Products Regulatory Authority 
and the Pharmaceutical Society of Ireland. The Bill would establish a parallel 
system of regulation, duplicating the functions of the current one, and would 
allow a substance which has not received authorisation from the HPRA to be 
considered a medicine – an unusual departure which would subvert the agency’s 
regulatory authority, ignore its expert advice that cannabis is not capable of 
being authorised as a medicine2, and could create an undesirable precedent. 
The Cannabis Regulatory Authority would duplicate the functions of The Health 
Products Regulatory Authority [HPRA]. Advocates of the Bill state that the HPRA 
is not willing to regulate cannabis. It is not possible to regulate the whole plant 
                                                          
1
 Available here: http://www.oireachtas.ie/parliament/media/committees/health/32H003-Report-on-
Medicinal-Cannabinoids.pdf 
2
 As stated in “Cannabis for Medical Use – A Scientific Review”, HPRA, 2017, 
https://www.hpra.ie/docs/default-source/publications-forms/newsletters/cannabis-for-medical-use---a-
scientific-review.pdf?Status=Master&sfvrsn=7 
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extract of a plant which has over 100 varieties and several hundred components. 
Authorised medicines must be of high quality, safe and effective. 
Removal of cannabis as a controlled substance 
The Committee is also concerned that the Bill proposes to remove cannabis from 
the Misuse of Drugs Act 1977 as a controlled substance, meaning that it could 
have major unintended policy consequences, decriminalising cannabis in non-
medicinal circumstances. This seems in conflict with the intention of the Bill 
which is to make cannabis available specifically for medicinal use as expressed in 
the title of the Bill. It is the view of the committee that this is not a safe course 
of action as the cannabis plant has many psychoactive effects which are 
potentially harmful. 
The Bill is as much about decriminalising the use of cannabis as it is about 
promoting it for medicinal use. The Minister for Justice and Equality is the 
relevant Minister quoted in the Bill. 
Framework of access to cannabis 
Furthermore, the system of access to medicinal cannabis proposed in the Bill, 
appears to the Committee to be too loose to effectively guard against (a) 
leakage of supply to recreational users, (b) overuse by patients, and (c) 
unanticipated harmful use due to interactions with other medicines or other 
medical circumstances for individual patients. 
This is largely because the level of involvement of medical professionals in 
patients’ engagement with cannabis, as outlined by the Bill, is in the 
Committee’s view insufficient. The Bill allows a doctor to certify a person as 
having a condition which can be reasonably treated by cannabis, without having 
to stipulate a dosage amount or a finite period of time for treatment. There is 
also no provision in the Bill for stipulating the type of cannabinoid product a 
patient should be treated with, even though different cannabinoid ratios have 
shown different efficacy for different conditions. There is no reference in the Bill 
regarding the medical indications for cannabis certification by a doctor other 
than the patient has a condition which a trial of cannabis or cannabis based 
product is a reasonable course of action. 
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Certification from a doctor that a patient “has a condition for which a trial of 
cannabis or cannabis-based product is a reasonable course of treatment to 
improve symptoms or cause of the condition”(section 32 of the Bill), for a 
product which has no authorisation by the HPRA, would raise many legal and 
medical indemnity issues. A certificate is fundamentally different to a 
prescription. Evidence was given to the Committee by the Bill’s sponsor’s adviser 
that a doctor’s certification is to be used as evidence to protect the holder of the 
certificate from prosecution and unnecessary criminalisation if found in 
possession of cannabis. 
Evidence was given to the Committee that regulation of medicinal cannabis was 
key to its availability, yet the Bill does not define what the term medicinal 
cannabis means, therefore it would be very difficult to regulate. 
Embedded in the cannabis plant are cannabinoids, which act on the 
endocannabinoid system in the human body, and have medicinal properties. 
However, whole plant cannabis also contains many other chemicals which are 
psychoactive and potentially harmful. It is not possible to regulate the whole 
plant extract of a plant which has over 100 varieties and several hundred 
components. The isolation of cannabinoids which have proven medicinal 
beneficial effects and have scientifically proven efficacy and safety is the key to 
developing medicinal cannabis products which can be legally prescribed and 
dispensed. 
Further, labelling of the product would indicate its contents however it is unclear 
how this would be achieved given the numerous varieties of cannabis plants and 
their multiplicity of components. 
Although the Bill limits the maximum amount of cannabis to be sold per 
transaction as one ounce, the Committee cannot identify any provision which 
limits the number of transactions. The Committee also cannot identify any 
provision in the Bill for medical follow-up or supervision beyond initial 
certification, e. g. to monitor potential negative side effects or interaction with 
other medicines. The Committee is therefore worried that any individual who 
receives certification from a doctor once would then be able to buy as much 
cannabis as they want indefinitely, without continued medical supervision. 
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Normally medication is prescribed with reference to strength in milligrammes 
and gives instructions on frequency and length of use. Such stipulations are not 
mentioned in the Bill. 
The sponsor of the Bill proposed that whole or full plant extract would be made 
available in whatever form, including smoking cannabis, when used for medicinal 
purposes. The method of consumption would at the patient’s prerogative. It is 
the Committee’s view that this would lead to the leakage of whole plant cannabis 
from medicinal use to recreational use in the general population. 
The Committee also wishes to draw attention to the use of the word “consumer” 
in the Bill to describe medicinal users of cannabis, the Bill’s use of imperial 
measurements and the fact that a previous conviction for possessing cannabis 
would not disqualify a person from holding a licence to sell cannabis, all of which 
it views as inappropriate. 
Also, the Bill suggests that the proposed Cannabis Research Institute  would 
commission research on cannabis for recreational use as well as medicinal use. 
Additionally the Institute would promote public awareness of cannabis and its 
safe use. This element of the Bill seems contrary to the purpose of the Bill. 
Overall approach of the Bill 
Although the Committee has outlined a number of discrete problems in the 
drafting of the Bill, some of which may be more easily fixed through amendment 
than others, the underlying approach of the Bill proposes a system of access to 
medicinal cannabis that is much looser than the Committee considers prudent. 
Therefore, a central element of the Bill is irreconcilable with the Committee’s 
views on how medicinal cannabis should be approached. The Committee favours 
a gradual introduction of medicinal cannabis which is evidence-led for each 
condition that access is approved for, which is endorsed by the usual regulatory 
authority for medicines in this jurisdiction and which has the benefit of close 
monitoring by medical professionals of the effects of treatment. 
In that regard, the Committee is cognisant of the HPRA’s advice that “medical 
use of cannabis should only be initiated as part of a structured process of formal 
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on-going clinical evaluation by a medical consultant, in a limited number of 
clearly defined medical conditions.3” 
The Committee has been informed that such an approach is being pursued by 
the Minister for Health and his officials. Department Officials told the Committee, 
at its engagement with them of 13 April, that an expert reference group has 
been established which is currently drafting guidelines to facilitate the use of 
cannabis treatments under an access programme, its work being informed by 
the HPRA’s report. The Committee also understands that the Department will 
progress Statutory Instruments to advance the access programme. The 
Committee views such an access programme as a more careful and desirable 
method of introducing medicinal cannabis to Ireland, and therefore views the 
continued advancement of the Bill under scrutiny as duplicative and undermining 
of the access programme process. 
 
 
 
 
 
 
 
 
 
 
 
                                                          
3
 “Cannabis for Medical Use – A Scientific Review”, HPRA, 2017, https://www.hpra.ie/docs/default-
source/publications-forms/newsletters/cannabis-for-medical-use---a-scientific-
review.pdf?Status=Master&sfvrsn=7 
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Implications of the Bill for existing legislation 
Having received legal advice, the Committee is satisfied that enacting the Bill as 
it exists would create legislative contradictions between the Bill and existing 
Acts. Resolving such contradictions by amendment of this Bill, or of other Acts, 
appears to the Committee to be an onerous undertaking, quite apart from the 
further re-drafting which would be necessary to avoid undesirable policy 
consequences. 
The Bill may necessitate amendment to the Health Acts 1947 to 2015, the 
Pharmacopeia Acts 1931 and 1977, the Poisons Acts 1961 and 1977 and the 
Pharmacy Acts 1875 to 1977 - and other legislation - affected by the medicinal 
prescription of cannabis.  
Section 17 of the Bill relates to medicinal use retail licences and such licences 
may only be granted in respect of registered pharmacies. The law relating to 
pharmacists and pharmacies may therefore need to be amended, possibly 
extensively. 
Problems and inconsistencies for criminal justice legislation which could be 
created by the enactment of the Bill include but are not limited to: 
- Differing definitions of cannabis between the Bill and the Misuse of Drugs Act 
1977, which creates a possibility that the differing interpretations could be 
exploited in the criminal justice context. 
 - The possible need for section 5(1) (b) of the Criminal Justice (Psychoactive 
Substances) Act 2010 and section 5 of the Misuse of Drugs Act 1984 (and 
Regulation 28 of SI 173 of 2017) to be amended to explicitly exclude medicinal 
cannabis from their prohibitions against promoting psychoactive and controlled 
substances, so that they do not conflict with section 6 (2) (e) and (f) of the Bill, 
which deal with the Cannabis Regulatory Authority’s promoting understanding of 
medicinal cannabis. 
- The Bill’s creation of offences without prescribing corresponding penalties 
conflicts with the 1977 Act, which provides both offences and penalties. 
- Sections 16, 18 and 19 of the Bill respectively provide for licences to 
wholesale, import, and cultivate cannabis. The Committee understands that 
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these would require the amendment of sections 3, 15, 15A, 15B, 17, 19 of the 
1977 Act. 
- Section 3 of the Criminal Justice Act 1994, which defines “drug trafficking”, 
might need to be amended to include an exception for medicinal cannabis. 
- Section 15 of the 1977 Act would need to be amended to allow a parent to give 
medicinal cannabis to their child. 
- The Committee understands that sections 42 and 43 of the Bill as drafted 
would legalise cannabis entirely, as the 1977 Act would cease to apply to 
cannabis. This seems to conflict with the intention of the Bill, which is to make 
cannabis available specifically in a medicinal context. If these sections were to 
proceed without significant amendment, they may also necessitate amendment 
of the Criminal Justice (Spent Convictions and Certain Disclosures) Act 2016, as 
well as having complicated implications for extradition law. 
- Section 43 (1) of the Bill would alter the application of commitments made by 
Ireland under an international treaty, which would require corresponding action 
from Ireland at an inter-State level.  
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Recommendation to the Dáil 
Based on its consideration, as outlined above, the Committee has determined 
that the Bill has technical issues and implementation difficulties, that it may 
have unintended policy consequences (including leakage of supply of cannabis to 
recreational markets and a lack of safeguards against harmful use of cannabis 
by patients), that there are major legal issues (the numerous amendments 
which would be necessary to reconcile the Bill with existing law would be 
onerous), and that access to medicinal cannabis in Ireland would be better 
achieved through an access programme and secondary legislation, which the 
Committee has been informed is under preparation. 
Therefore, the Committee recommends that the Cannabis for Medicinal Use 
Regulation Bill 2016 should not proceed to Committee stage. 
 
 
__________________ 
Michael Harty T.D. 
Chair 
Joint Committee on Health  
12 July 2017 
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Appendix 1 – Committee Membership 
 
Deputies:    
 
Bernard Durkan (Fine Gael) 
Dr. Michael Harty (Rural Independent Technical Group) 
Billy Kelleher (Fianna Fáil) 
Alan Kelly (Labour) 
Kate O'Connell (Fine Gael) 
Margaret Murphy O'Mahony (Fianna Fáil) 
Louise O'Reilly (Sinn Féin) 
 
Senators:   
 
Colm Burke (Fine Gael) 
John Dolan (Civil Engagement Technical Group) 
Rónán Mullen (Independent) 
Dr. Keith Swanick (Fianna Fáil) 
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Appendix 2 – Terms of Reference of Committee 
 
JOINT COMMITTEE ON HEALTH  
 
TERMS OF REFERENCE 
 
a. Functions of the Committee – derived from Standing Orders [DSO 84A; SSO 70A] 
 
(1) The Select Committee shall consider and report to the Dáil on— 
(a) such aspects of the expenditure, administration and policy of a 
Government Department or Departments and associated public 
bodies as the Committee may select, and 
(b) European Union matters within the remit of the relevant Department 
or Departments. 
(2) The Select Committee appointed pursuant to this Standing Order may be 
joined with a Select Committee appointed by Seanad Éireann for the 
purposes of the functions set out in this Standing Order, other than at 
paragraph (3), and to report thereon to both Houses of the Oireachtas. 
(3) Without prejudice to the generality of paragraph (1), the Select 
Committee appointed pursuant to this Standing Order shall consider, in 
respect of the relevant Department or Departments, such— 
(a) Bills, 
(b) proposals contained in any motion, including any motion within the 
meaning of Standing Order 187, 
(c) Estimates for Public Services, and  
(d) other matters 
 
as shall be referred to the Select Committee by the Dáil, and 
(e) Annual Output Statements including performance, efficiency and 
effectiveness in the use of public monies, and 
(f) such Value for Money and Policy Reviews as the Select Committee 
may select. 
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(4) The Joint Committee may consider the following matters in respect of 
the relevant Department or Departments and associated public bodies: 
(a) matters of policy and governance for which the Minister is officially 
responsible, 
(b) public affairs administered by the Department, 
(c) policy issues arising from Value for Money and Policy Reviews 
conducted or commissioned by the Department, 
(d) Government policy and governance in respect of bodies under the 
aegis of the Department, 
(e) policy and governance issues concerning bodies which are partly or 
wholly funded by the State or which are established or appointed 
by a member of the Government or the Oireachtas, 
(f) the general scheme or draft heads of any Bill, 
(g) any post-enactment report laid before either House or both Houses 
by a member of the Government or Minister of State on any Bill 
enacted by the Houses of the Oireachtas, 
 
(h) statutory instruments, including those laid or laid in draft before 
either House or both Houses and those made under the European 
Communities Acts 1972 to 2009, 
(i) strategy statements laid before either or both Houses of the 
Oireachtas pursuant to the Public Service Management Act 1997, 
(j) annual reports or annual reports and accounts, required by law, and 
laid before either or both Houses of the Oireachtas, of the 
Department or bodies referred to in subparagraphs (d) and (e) and 
the overall performance and operational results, statements of 
strategy and corporate plans of such bodies, and 
(k) such other matters as may be referred to it by the Dáil from time 
to time. 
(5) Without prejudice to the generality of paragraph (1), the Joint 
Committee appointed pursuant to this Standing Order shall consider, in 
respect of the relevant Department or Departments— 
(a) EU draft legislative acts standing referred to the Select Committee 
under Standing Order 114, including the compliance of such acts 
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with the principle of subsidiarity, 
(b) other proposals for EU legislation and related policy issues, 
including programmes and guidelines prepared by the European 
Commission as a basis of possible legislative action, 
(c) non-legislative documents published by any EU institution in 
relation to EU policy matters, and 
(d) matters listed for consideration on the agenda for meetings of the 
relevant EU Council of Ministers and the outcome of such 
meetings. 
(6) Where a Select Committee appointed pursuant to this Standing Order 
has been joined with a Select Committee appointed by Seanad Éireann, 
the Chairman of the Dáil Select Committee shall also be the Chairman of 
the Joint Committee. 
(7) The following may attend meetings of the Select or Joint Committee 
appointed pursuant to this Standing Order, for the purposes of the 
functions set out in paragraph (5) and may take part in proceedings 
without having a right to vote or to move motions and amendments: 
(a) Members of the European Parliament elected from constituencies in 
Ireland, including Northern Ireland, 
(b) Members of the Irish delegation to the Parliamentary Assembly of 
the Council of Europe, and 
(c) at the invitation of the Committee, other Members of the European 
Parliament. 
(8) A Select Committee appointed pursuant to this Standing Order may, in 
respect of any Ombudsman charged with oversight of public services 
within the policy remit of the relevant Department or Departments, 
consider— 
 
(a) such motions relating to the appointment of an Ombudsman as 
may be referred to the Committee, and 
 
(b) such Ombudsman reports laid before either or both Houses of the 
Oireachtas as the Committee may select. 
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b. Scope and Context of Activities of Committees (as derived from Standing Orders) [DSO 
84; SSO 70] 
 
(1) The Joint Committee may only consider such matters, engage in such activities, 
exercise such powers and discharge such functions as are specifically authorised 
under its orders of reference and under Standing Orders; and 
(2)  Such matters, activities, powers and functions shall be relevant to, and shall arise 
only in the context of, the preparation of a report to the Dáil and/or Seanad. 
(3) The Joint Committee shall not consider any matter which is being considered, or 
of which notice has been given of a proposal to consider, by the Committee of 
Public Accounts pursuant to Standing Order 186 and/or the Comptroller and 
Auditor General (Amendment) Act 1993; and 
(4) any matter which is being considered, or of which notice has been given of a 
proposal to consider, by the Joint Committee on Public Petitions in the exercise of 
its functions under Standing Orders [DSO 111A and SSO 104A]. 
(5) The Joint Committee shall refrain from inquiring into in public session or 
publishing confidential information regarding any matter if so requested, for 
stated reasons given in writing, by— 
(a) a member of the Government or a Minister of State, or 
(b) the principal office-holder of a body under the aegis of a Department or 
which is partly or wholly funded by the State or established or 
appointed by a member of the Government or by the Oireachtas: 
Provided that the Chairman may appeal any such request made to the Ceann 
Comhairle / Cathaoirleach whose decision shall be final. 
(6) It shall be an instruction to all Select Committees to which Bills are referred that 
they shall ensure that not more than two Select Committees shall meet to 
consider a Bill on any given day, unless the Dáil, after due notice given by the 
Chairman of the Select Committee, waives this instruction on motion made by the 
Taoiseach pursuant to Dáil Standing Order 28. The Chairmen of Select 
Committees shall have responsibility for compliance with this instruction. 
 
